drugset / Trial / NCT06366347
ALPINE: Maintenance Letrozole/Abemaciclib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this study are: * Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) * Letrozole (a type of aromatase inhibitor)
Timeline
- Start
- 2024-09-25
- Primary completion
- 2027-09-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 4 ml | Intravenous |